| Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses MG Alameh, I Tombácz, E Bettini, K Lederer, S Ndeupen, C Sittplangkoon, ... Immunity 54 (12), 2877-2892. e7, 2021 | 505 | 2021 |
| The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory S Ndeupen, Z Qin, S Jacobsen, A Bouteau, H Estanbouli, BZ Igyártó Iscience 24 (12), 2021 | 401 | 2021 |
| Future considerations for the mRNA-lipid nanoparticle vaccine platform BZ Igyártó, S Jacobsen, S Ndeupen Current opinion in virology 48, 65-72, 2021 | 93 | 2021 |
| The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience 24 S Ndeupen, Z Qin, S Jacobsen, A Bouteau, H Estanbouli, BZ Igyártó Available at:, 2021 | 34 | 2021 |
| Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 immune responses S Ndeupen, A Bouteau, C Herbst, Z Qin, S Jacobsen, NE Powers, ... PLoS pathogens 18 (1), e1010255, 2022 | 31 | 2022 |
| The mRNA-LNP plat-form's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience. 2021; 24 (12): 103479 S Ndeupen, Z Qin, S Jacobsen, A Bouteau, H Estanbouli, BZ Igyártó J. ISCI, 2021 | 17 | 2021 |
| Single-cell suspension preparation from murine organs following in vivo mRNA-LNP exposure S Ndeupen, Z Qin, BZ Igyártó STAR protocols 3 (2), 101350, 2022 | 5 | 2022 |
